Regado Biosciences files for a $75 million IPO

By
A A A

Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company is backed by founder of Fastenal and former Minnesota Senator, Robert Kierlin, who holds a 27% stake.

The Basking Ridge, NJ-based company, which was founded in 2001 and booked no revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on 3/1/2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RGDO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com